
111, Inc.
YINASDAQHealthcareMedical - Distribution
Previous close
$3.57
+$0.13 · +3.78%
YI company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
35
Expensive
Momentum
26
Weakening
Sentiment
57
Mixed
Risk resilience
32
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBased in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
- Industry
- Medical - Distribution
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Junling Liu
- Listed since
- Sep 12, 2018
- Employees
- 1,063
Market position
Day range
Current $3.57
52-week range
Current $3.57
- Open
- $3.44
- Previous close
- $3.44
- Volume
- 5.48K
- 0.3× average
- Average volume
- 18.06K
- Average daily volume
- Market cap
- 31.19M USD
- Beta
- 0.67
- Market reference 1
- 50-day average
- $3.9406
- -9.40% below average
- 200-day average
- $5.1383
- -30.52% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -188.16M CNY
- P/E (TTM)
- -2.46×
- P/B (TTM)
- -1.97×
- P/S (TTM)
- 0.02×
- EV / EBITDA
- -103.85×
- Earnings yield
- -10.81%
- Free cash flow yield
- 73.63%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 5.74%
- Operating margin
- -0.24%
- Net margin
- -0.66%
- Return on equity
- 2.40%
- Return on assets
- -0.77%
- Return on invested capital
- -2.31%
Financial health
- Debt / equity
- -0.38×
- Current ratio
- 1.09×
- Altman Z-score
- 37.97
- Piotroski F-score
- 1 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 12.21B CNY | 14.4B CNY | 14.95B CNY | 13.52B CNY | 12.43B CNY |
| Cost of goods sold | 11.51B CNY | 13.57B CNY | 14.1B CNY | 12.68B CNY | 11.8B CNY |
| Gross profit | 703.7M CNY | 829.23M CNY | 848.98M CNY | 839.98M CNY | 621.1M CNY |
| Selling, general, and administrative | 654.98M CNY | 384.8M CNY | 672.59M CNY | 663.5M CNY | 720.13M CNY |
| Operating expenses | 713.73M CNY | 827.12M CNY | 1.2B CNY | 1.21B CNY | 1.26B CNY |
| Interest income | 3.78M CNY | 7.04M CNY | 8.83M CNY | 8.12M CNY | 9.78M CNY |
| Interest expense | 34.6M CNY | 28.33M CNY | 20.14M CNY | 13.44M CNY | 5.49M CNY |
| Depreciation and amortization | 11.84M CNY | 16.97M CNY | 21.78M CNY | 40.82M CNY | 27.22M CNY |
| Operating income | −10.03M CNY | 2.11M CNY | −350.1M CNY | −371M CNY | −642.14M CNY |
| Net income | −16.84M CNY | −64.74M CNY | −392.69M CNY | −416.88M CNY | −669.81M CNY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -0.6
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
YI news
YI peers
Continue in GoAI
Research YIresearch.disclaimer







